MedTrace Logo

Metformin in Non-Alcoholic Fatty Liver Disease

NCT00303537 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2007-07-02

No results posted yet for this study

Summary

The study evaluates the use of the antidiabetic medicine metformin in nonalcoholic fatty liver disease.

Conditions

Interventions

DRUG

metformin

Sponsors & Collaborators

Principal Investigators

  • Kaare Birkeland, Prof./Ph.D · Aker University Hospital, Oslo, Norway

  • Zbigniew Konopski, Cons./Ph.D · Aker University Hospital, Oslo, Norway

  • Kristian Bjøro, Cons./Ph.D · Rikshospitalet-Radiumhospitalet, Oslo, Norway

  • John W Haukeland, Physician · University Hospital, Aker

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2008-06-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00303537 on ClinicalTrials.gov